| Literature DB >> 33419781 |
Lambros Tselikas1,2, Stephane Champiat3, Rahul A Sheth4, Steve Yevich4, Samy Ammari5, Frederic Deschamps6, Siham Farhane3, Charles Roux6, Sandrine Susini2, Severine Mouraud2, Alexandre Delpla6, Thibault Raoult7, Caroline Robert8,9, Christophe Massard3,9, Fabrice Barlesi9, Jean-Charles Soria9, Aurélien Marabelle2,3, Thierry de Baere6,9.
Abstract
Human intratumoral immunotherapy (HIT-IT) is under rapid development, with promising preliminary results and high expectations for current phase III trials. While outcomes remain paramount for patients and the referring oncologists, the technical aspects of drug injection are critical to the interventional radiologist to ensure optimal and reproducible outcomes. The technical considerations for HIT-IT affect the safety, efficacy, and further development of this treatment option. Image-guided access to the tumor allows the therapeutic index of a treatment to be enhanced by increasing the intratumoral drug concentration while minimizing its systemic exposure and associated on-target off-tumor adverse events. Direct access to the tumor also enables the acquisition of cancer tissue for sequential sampling to better understand the pharmacodynamics of the injected immunotherapy and its efficacy through correlation of immune responses, pathologic responses, and imaging tumor response. The aim of this article is to share the technical insights of HIT-IT, with particular consideration for patient selection, lesion assessment, image guidance, and technical injection options. In addition, the organization of a standard patient workflow is discussed, so as to optimize HIT-IT outcome and the patient experience. ©2021 American Association for Cancer Research.Entities:
Mesh:
Year: 2021 PMID: 33419781 DOI: 10.1158/1078-0432.CCR-19-4073
Source DB: PubMed Journal: Clin Cancer Res ISSN: 1078-0432 Impact factor: 12.531